autologous CD34+ cells transduced with WASP lentiviral vector / Genethon, Boston Children's Hospital - LARVOL DELTA

WAS FUP: Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (clinicaltrials.gov) - P1/2; N=10; Active, not recruiting; Sponsor: Genethon; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2027 ➔ Oct 2032; Trial primary completion date: Dec 2027 ➔ Oct 2032

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Gene Therapies • Immunology • Primary Immunodeficiency

Gene Therapy for Wiskott-Aldrich Syndrome (WAS) (clinicaltrials.gov) - P1/2; N=6; Completed; Sponsor: Genethon; Recruiting ➔ Completed

Clinical • Trial completion